DE69619753T2 - Verwendung mindestens eines die Tripeptidsequenz Lys-DPro-Arg enthaltenden Peptids zur Herstellung eines Arzneimittels zur Behandlung einer Entzündung - Google Patents

Verwendung mindestens eines die Tripeptidsequenz Lys-DPro-Arg enthaltenden Peptids zur Herstellung eines Arzneimittels zur Behandlung einer Entzündung

Info

Publication number
DE69619753T2
DE69619753T2 DE69619753T DE69619753T DE69619753T2 DE 69619753 T2 DE69619753 T2 DE 69619753T2 DE 69619753 T DE69619753 T DE 69619753T DE 69619753 T DE69619753 T DE 69619753T DE 69619753 T2 DE69619753 T2 DE 69619753T2
Authority
DE
Germany
Prior art keywords
dpro
arg
inflammation
medicament
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69619753T
Other languages
English (en)
Other versions
DE69619753D1 (de
Inventor
Yann Mahe
Bruno Buan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LOreal SA filed Critical LOreal SA
Publication of DE69619753D1 publication Critical patent/DE69619753D1/de
Application granted granted Critical
Publication of DE69619753T2 publication Critical patent/DE69619753T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/02—Preparations for cleaning the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/70—Biological properties of the composition as a whole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Birds (AREA)
  • Genetics & Genomics (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
DE69619753T 1995-09-19 1996-08-13 Verwendung mindestens eines die Tripeptidsequenz Lys-DPro-Arg enthaltenden Peptids zur Herstellung eines Arzneimittels zur Behandlung einer Entzündung Expired - Lifetime DE69619753T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9510977A FR2738746B1 (fr) 1995-09-19 1995-09-19 Utilisation d'au moins un peptide dans une composition cosmetique ou pour la preparation d'un medicament

Publications (2)

Publication Number Publication Date
DE69619753D1 DE69619753D1 (de) 2002-04-18
DE69619753T2 true DE69619753T2 (de) 2002-08-08

Family

ID=9482701

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69619753T Expired - Lifetime DE69619753T2 (de) 1995-09-19 1996-08-13 Verwendung mindestens eines die Tripeptidsequenz Lys-DPro-Arg enthaltenden Peptids zur Herstellung eines Arzneimittels zur Behandlung einer Entzündung

Country Status (12)

Country Link
US (2) US20050026845A1 (de)
EP (1) EP0764444B1 (de)
JP (1) JP2831979B2 (de)
AR (1) AR003589A1 (de)
CA (1) CA2185932C (de)
DE (1) DE69619753T2 (de)
ES (1) ES2174039T3 (de)
FR (1) FR2738746B1 (de)
MX (1) MX9710252A (de)
PL (1) PL186767B1 (de)
RU (1) RU2180590C2 (de)
WO (1) WO1997010838A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2784028B1 (fr) * 1998-10-01 2003-02-07 Oreal Utilisation d'un peptide prevenant les reactions d'intolerance de la peau, notamment dans des compositions cosmetiques
US6803044B1 (en) 1999-03-24 2004-10-12 Zengen, Inc. Antimicrobial and anti-inflammatory peptides for use in human immunodeficiency virus
US6887846B2 (en) 1999-03-24 2005-05-03 Zengen, Inc. Antimicrobial amino acid sequences derived from alpha-melanocyte-stimulating hormone
US7402559B2 (en) 1999-03-24 2008-07-22 Msh Pharma, Incorporated Composition and method of treatment for urogenital conditions
US6800291B1 (en) 1999-03-24 2004-10-05 Zengen, Inc. Uro-genital condition treatment system
ES2286876T3 (es) * 1999-10-04 2007-12-01 L'oreal Uso de un peptido que previene las reacciones de ijntolerancia de la piel, en particular en composiciones cosmeticas.
US6780838B2 (en) 2001-01-29 2004-08-24 Zengen, Inc. Compounds for treating fungal pathologies of the oral cavity
US6894028B2 (en) 2001-04-06 2005-05-17 Zengen, Inc. Use of KPV tripeptide for dermatological disorders
FR2826263B1 (fr) * 2001-06-26 2005-02-25 Oreal Composition cosmetique ou dermatologique comprenant une association entre un compose inhibiteur de l'elastase de la famille des n-acylaminoamides et au moins un compose anti-inflammatoire
FR2826580B1 (fr) * 2001-06-29 2005-09-30 Oreal Utilisation du tripeptide lys-pro-val (kpv) pour favoriser le renouvellement epidermique et la micro-cicatrisation cutanee superficielle et/ou ameliorer l'aspect esthetique des plaies et cicatrices
FR2826581B1 (fr) * 2001-06-29 2005-10-07 Oreal Utilisation du tripeptide lys-pro-val (kpv) dans le traitement des melanomes
FR2827170B1 (fr) * 2001-07-13 2004-07-16 Soc Extraction Principes Actif Utilisation de peptides pour augmenter l'adhesion cellulaire
US7115574B2 (en) 2001-12-10 2006-10-03 Zengen, Inc. System and method for support legacy operating system booting in a legacy-free system
US6939846B2 (en) 2001-12-17 2005-09-06 Zengen, Inc. Use of a polypeptide for treatment of pruritis in animals
FR2846883B1 (fr) * 2002-11-08 2004-12-24 Vincience Composition cosmetique comprenant, comme ingredient actif, au moins un peptide et utilisation de ce peptide
ATE505199T1 (de) * 2002-11-08 2011-04-15 Soc Extraction Principes Actif Pharmazeutische, kosmetische oder therapeutische zusammensetzungen enthaltend peptide mit dem motiv arg-gly-ser
WO2005120554A1 (en) * 2004-06-14 2005-12-22 Cognis France S.A.S. Cosmetic preparations containing pth fragments
US7300649B2 (en) 2005-02-11 2007-11-27 Genepharm, Inc. Cosmetic and cosmeceutical compositions for restoration of skin barrier function
EP2509994B1 (de) * 2009-12-08 2018-09-26 AMSilk GmbH Seidenproteinbeschichtungen
WO2014159798A1 (en) 2013-03-13 2014-10-02 Avery Dennison Corporation Improving adhesive properties
SG11201602161XA (en) * 2013-09-23 2016-04-28 Wolff August Gmbh & Co Kg Arzneimittel Dr Anti-inflammatory tripeptides
KR102208853B1 (ko) * 2018-05-08 2021-01-28 오션펩 주식회사 주름개선 효능을 갖는 펩티드

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5157023A (en) * 1984-08-21 1992-10-20 Lipton James M Antipyretic and anti-inflammatory lys pro val compositions and method of use
US5028592A (en) * 1986-08-08 1991-07-02 Lipton James M Antipyretic and anti-inflammatory peptides
US4878744A (en) * 1985-12-30 1989-11-07 Capitol Records, Inc. Three dimensional reflex lens systems
CH676425A5 (de) * 1986-08-08 1991-01-31 Univ Texas
GB8807427D0 (en) * 1988-03-28 1988-05-05 National Biological Standards Board Peptides
IL89770A (en) * 1988-03-28 1994-12-29 British Tech Group Analgesic peptides and pharmaceutical compositions containing them and the process for the preparation of some such compounds
FR2784028B1 (fr) * 1998-10-01 2003-02-07 Oreal Utilisation d'un peptide prevenant les reactions d'intolerance de la peau, notamment dans des compositions cosmetiques

Also Published As

Publication number Publication date
RU2180590C2 (ru) 2002-03-20
DE69619753D1 (de) 2002-04-18
JP2831979B2 (ja) 1998-12-02
CA2185932C (fr) 2003-11-11
EP0764444A1 (de) 1997-03-26
FR2738746B1 (fr) 1997-11-14
CA2185932A1 (fr) 1997-03-20
PL324485A1 (en) 1998-05-25
US20050026845A1 (en) 2005-02-03
FR2738746A1 (fr) 1997-03-21
WO1997010838A1 (fr) 1997-03-27
PL186767B1 (pl) 2004-02-27
US20080038208A1 (en) 2008-02-14
EP0764444B1 (de) 2002-03-13
MX9710252A (es) 1998-03-31
ES2174039T3 (es) 2002-11-01
AR003589A1 (es) 1998-08-05
JPH09124502A (ja) 1997-05-13

Similar Documents

Publication Publication Date Title
DE69619753T2 (de) Verwendung mindestens eines die Tripeptidsequenz Lys-DPro-Arg enthaltenden Peptids zur Herstellung eines Arzneimittels zur Behandlung einer Entzündung
DE69435116D1 (de) Verwendung von Botulinumtoxin für die Herstellung eines Arzneimittels zur Linderung von Rückenschmerzen
DE69630479D1 (de) Arzneimittel zur Behandlung von entzündlichen Herzkrankheiten
BR9606607A (pt) Composto método de aperfeiçoamento de transporte de uma droga ou outro ativo método de fabricação de um medicamento composto uso método de tratamento de uma doença e método de preparação de um medicamento
ATE195527T1 (de) Neue steroidester zur behandlung von hauterkrankungen
DE69925488D1 (de) Verwendung von fk506 und verwandten makroliden zur herstellung eines medikaments für die behandlung und vorbeugung von schmerzen
DE69637449D1 (de) Verwendung von alpha-hydroxysäuren zur herstellung eines arzneimittels für die behandlung von entzündungen
DE69600983T2 (de) Kapselpräparate zur Behandlung von Pflanzen
DE69417115T2 (de) Verfahren zur Herstellung chirurgischen Nahtmaterials
DE69635298D1 (de) Verwendung von Acetylsalicylsäuren zur Herstellung eines Medikaments für die Behandlung von Hautverletzungen
ATE246518T1 (de) Egr-1 zur herstellung eines medikamentes zur behandlung von wunden
ATE221763T1 (de) Die verwendung von glyceryltriacetat zur behandlung von onychomykosen
DE69534325D1 (de) Peptide zur behandlung von krebs
DE69318909D1 (de) Verfahren zur Herstellung von menschlichem Wachstumshormon
DE59810043D1 (de) Verfahren zur Herstellung eines pharmazeutisch aktiven Peptides
DE69614739T2 (de) Pflaster zur Behandlung von Pflanzen
DE69423577T2 (de) Verwendung von Oenothein B zur Herstellung eines Medikaments zur Behandlung der durch Hyperandrogenität bedingte Störungen.
DE69632677D1 (de) Verwendung eines Rifamycin-Derivates zur Herstellung eines Medikamentes zur Behandlung von Krankheiten verursacht durch Helicobacter pylori-Infektionen
NO973366D0 (no) Fremgangsmåte for behandling av multippel sklerose
ATE190494T1 (de) Verwendung von gnrh-antagonisten zur herstellung eines medikaments zur behandlung gonaden-steroid abhängiger erkrankungen
DE69620786D1 (de) Verwendung von cholinesterase-inhibitoren für die herstellung eines medikaments zur behandlung von xerostomie
DE69300037T2 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
DE69632117D1 (de) Verwendung von 8,9-Dehydroestron zur Herstellung eines Arzneimittels zur Behandlung von durch freie Radikale verursachte Krankheiten
DE69739190D1 (de) Arzneimittel zur behandlung von oculären kreislauferkrankungen
DE69610045D1 (de) Verwendung eines Rohpflanzenextraktes zur Herstellung eines Arzneimittels zur Behandlung von HIV-Infektionen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition